XenoPort/Astellas's gabapentin prodrug filed for restless legs in Japan
This article was originally published in Scrip
Astellas has submitted an approval application in Japan for gabapentin enacarbil (ASP8825) for the treatment of restless legs syndrome (RLS).
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.